Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2026 | PREPEC (OPBC-02): pre-pectoral vs sub-pectoral IBBR after mastectomy

Walter Weber • 30 May 2026
ASCO 2026
Breast Cancer
PREPEC

Walter Weber, MD, University Hospital Basel, Basel, Switzerland, discusses findings from the Phase III PREPEC (OPBC-02) trial (NCT04293146) comparing pre-pectoral and sub-pectoral implant-based breast reconstruction (IBBR) following mastectomy for breast cancer treatment or prevention. Pre-pectoral IBBR significantly improved long-term quality of life compared with sub-pectoral IBBR, though at the cost of a higher risk of implant loss or replacement, informing surgical decision-making in this setting. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Walter Weber

Pre-pectoral IBBR and oncologic safety following mastectomy
1:20
Pre-pectoral IBBR and oncologic safety following mastectomy
Walter Weber • 30 May 2026
Results from the PREPEC trial support pre-pectoral positioning for IBBR following mastectomy
0:48
Results from the PREPEC trial support pre-pectoral positioning for IBBR following mastectomy
Walter Weber • 30 May 2026
Evaluating the role of axillary surgery after neoadjuvant chemotherapy
2:12
Evaluating the role of axillary surgery after neoadjuvant chemotherapy
Walter Weber • 13 Mar 2025
Current indications for axillary dissection in breast cancer
1:28
Current indications for axillary dissection in breast cancer
Walter Weber • 13 Mar 2025

Related Videos

How will SARMs fit into the current breast cancer treatment paradigm?
1:14
How will SARMs fit into the current breast cancer treatment paradigm?
Rafael Grochot • 2 Jul 2026
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
1:35
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
Rafael Grochot • 2 Jul 2026
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
1:07
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
Sanjoy Chatterjee • 17 May 2026
Design and aim of the HYPORT study in regional nodal breast cancer
1:23
Design and aim of the HYPORT study in regional nodal breast cancer
Sanjoy Chatterjee • 17 May 2026
The content of VJOncology is intended for healthcare professionals